HopeStage
Back to all studies
CompletedNCT00422214

Extended-release quetiapine for bipolar depression

About this title

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

Read the official source — NCT00422214
Medication studyAges 18–65United StatesBipolarity
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 53 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2006
Recruitment status
Completed
Enrollment listed in the registry
400
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00422214
Official title
Show the full official title

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Phoenix · Scottsdale

51 more locations
  • Little Rock
  • Cerritos
  • La Mesa
  • Los Angeles
  • Newport Beach
  • Northridge
  • Oceanside
  • Pico Rivera
  • San Diego
  • Wildomar
  • Washington D.C.
  • Bradenton
  • Fort Lauderdale
  • Jacksonville
  • Leesburg
  • Maitland
  • North Miami
  • Orlando
  • Tampa
  • West Palm Beach
  • Smyrna
  • Honolulu
  • Joliet
  • Greenwood
  • Indianapolis
  • Wichita
  • Shreveport
  • Rockville
  • Farmington Hills
  • St Louis
  • Cherry Hill
  • Clementon
  • Brooklyn
  • New York
  • Staten Island
  • Beachwood
  • Cincinnati
  • Dayton
  • Oklahoma City
  • Portland
  • Salem
  • Philadelphia
  • Charleston
  • Memphis
  • Dallas
  • Houston
  • Charlottesville
  • Virginia Beach
  • Bellevue
  • Seattle
  • South Kirkland

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine fumarate (Seroquel) SR.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies